Adverse reactions and challenges with patient adherence to therapy are explored by dry eye disease experts.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Kabiri discusses limitations of existing dry eye disease (DED) treatments. Patients may not understand what constitutes good DED outcomes compared with temporary relief with over-the-counter drops. Prescription immunomodulators can take weeks to months for noticeable improvement, may cause more installation discomfort than patients expect based on past experience, and have a different timeline for perceived benefit. This can lead some patients to discontinue treatment prematurely.
Parekh reviews common adverse events with DED treatments such as burning, stinging, and taste issues with cyclosporine ophthalmic emulsion (Restasis) and its generics. Lack of familiarity with adverse effect profiles with new generics entering the market poses an additional challenge. It is important to educate patients up front on potential adverse events so that they understand what to expect, remain compliant, and follow up regularly to facilitate adherence. This comprehensive patient education around a predictable, tolerated treatment is key.
Kabiri notes unpredictability in ocular surface comfort and distribution with compounded topical cyclosporine formulations. Inconsistency between formulations can negatively impact patient experience, treatment adherence, provider confidence in managing DED, and outcomes.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.